Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GYRE 
Gyre Therapeutics Inc. (GYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: GYRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $19
1 Year Target Price $19
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.98% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 689.38M USD | Price to earnings Ratio 379.5 | 1Y Target Price 19 |
Price to earnings Ratio 379.5 | 1Y Target Price 19 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 6.11 - 19.00 | Updated Date 09/17/2025 |
52 Weeks Range 6.11 - 19.00 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.08% | Operating Margin (TTM) 8.11% |
Management Effectiveness
Return on Assets (TTM) 4.27% | Return on Equity (TTM) 7.84% |
Valuation
Trailing PE 379.5 | Forward PE 188.68 | Enterprise Value 636403237 | Price to Sales(TTM) 6.75 |
Enterprise Value 636403237 | Price to Sales(TTM) 6.75 | ||
Enterprise Value to Revenue 6.23 | Enterprise Value to EBITDA 55.52 | Shares Outstanding 90826777 | Shares Floating 20459640 |
Shares Outstanding 90826777 | Shares Floating 20459640 | ||
Percent Insiders 87.16 | Percent Institutions 3.78 |
Upturn AI SWOT
Gyre Therapeutics Inc.
Company Overview
History and Background
Gyre Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of liver diseases. Founded in 2016, the company has focused on developing novel drug candidates for nonalcoholic steatohepatitis (NASH) and other liver-related conditions. It went public via reverse merger in 2024.
Core Business Areas
- Drug Development: Focused on the discovery and development of novel therapeutics for liver diseases, particularly NASH, using a proprietary platform.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
The leadership team consists of experienced executives in drug development and the pharmaceutical industry. The organizational structure includes departments for research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- F351: F351 is a drug candidate for NASH. Currently in clinical trials. Market share data is not publicly available as the product is not yet commercialized. Competitors include Madrigal Pharmaceuticals (MDRL) and Viking Therapeutics (VKTX).
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the liver disease segment, is experiencing significant growth due to the increasing prevalence of NASH and other liver disorders. The market is characterized by intense competition and high regulatory hurdles.
Positioning
Gyre Therapeutics Inc. is positioning itself as a leader in the development of novel therapeutics for liver diseases, particularly NASH. Its competitive advantage lies in its proprietary platform and innovative drug candidates.
Total Addressable Market (TAM)
The global NASH market is expected to reach tens of billions of dollars in the coming years. Gyre Therapeutics Inc. is positioned to capture a share of this market with its drug candidate, F351.
Upturn SWOT Analysis
Strengths
- Proprietary drug development platform
- Focus on underserved liver disease market
- Experienced management team
- Novel drug candidates
Weaknesses
- Limited financial resources
- Dependence on single drug candidate
- High regulatory risk
- Lack of commercialization experience
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other liver diseases
- Positive clinical trial results
- Market growth in NASH
Threats
- Competition from larger pharmaceutical companies
- Failure of clinical trials
- Regulatory setbacks
- Generic entry
Competitors and Market Share
Key Competitors
- MDRL
- VKTX
- GILD
- ICPT
Competitive Landscape
Gyre Therapeutics Inc. faces significant competition from larger, more established pharmaceutical companies. Its success depends on its ability to differentiate its drug candidates and secure partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to being a relatively new company and recent IPO.
Future Projections: Future growth projections depend on the success of clinical trials and regulatory approvals for its drug candidates. Analyst estimates are not widely available.
Recent Initiatives: Recent strategic initiatives include advancing F351 through clinical trials and exploring partnerships for future development and commercialization.
Summary
Gyre Therapeutics is a new entrant in the biopharmaceutical sector focused on liver disease, particularly NASH. Its strength lies in its proprietary drug development platform and novel drug candidates. However, it faces challenges due to limited resources, competition, and regulatory risks. Future success hinges on positive clinical trial outcomes and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Industry reports
- Analyst reports (where available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is based on estimates due to the early stage of Gyre Therapeutics Inc.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gyre Therapeutics Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2006-04-12 | Interim CEO & Executive Chair Mr. Ping Zhang | ||
Sector Healthcare | Industry Biotechnology | Full time employees 579 | Website https://www.gyretx.com |
Full time employees 579 | Website https://www.gyretx.com | ||
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.